Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to .
INDIANAPOLIS, Aug. 9, 2023 /PRNewswire/ Eli Lilly and Company today announced the successful completion of its acquisition of DICE Therapeutics, Inc. . The acquisition expands Lilly s immunology.
Eli Lilly & Co. (LLY) Completes Acquisition of DICE Therapeutics (DICE) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Lilly Completes Acquisition Of Dice Therapeutics menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.